Belgium Oncology Clinical Trials Market Report 2022 to 2030

Belgium Oncology Clinical Trials Market Analysis

$ 3999

The Belgium oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $42.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. The market will be driven by increasing demand for innovative cancer therapies and a growing focus on personalized medicine. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Galapagos NV.

ID: IN10BECT006 CATEGORY: Clinical Trials GEOGRAPHY: Belgium AUTHOR: Vidhi Upadhyay

Buy Now

Belgium Oncology Clinical Trials Market Executive Summary

The Belgium oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $42.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. Belgium has by far the biggest per capita biopharmaceutical R&D spending in Europe. Belgian R&D spending per inhabitant grew by about 70% between 2016 and 2020, more than three times the growth rate of total EU27 R&D expenditures per inhabitant. In 2020, 68,782 new cancer diagnoses were recorded, with 31,942 new cases in women and 36,840 in males. Prostate cancer, lung cancer, and colorectal cancer were the most often diagnosed malignancies in males, while breast cancer, colorectal cancer, and lung cancer were the most commonly diagnosed cancers in women. With 500 new clinical trials approved each year, Belgium is among the top leaders in Europe in terms of clinical research per population.

In Belgium, oncology clinical trials are increasingly concentrating on personalized therapy. Various hospitals and research organizations in Belgium are involved in oncology clinical trials such as University Hospitals Leuven, Institut Jules Bordet, Antwerp University Hospital, Ghent University Hospital Cliniques, Universitaires Saint-Luc, and many more. Collaboration and cooperation between research institutes, hospitals, and industry are highly valued in Belgium. This allows clinical studies to be done more efficiently and precisely. In Belgium, oncology clinical trials use novel trial designs such as adaptive designs and basket trials. These designs make better use of resources and may assist to speed up the development of novel medicines.

belgium oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

With over 70 hospitals, including 7 academic hospitals, 12 universities with globally recognized life sciences departments and research teams, and over 50 pharmaceutical businesses involved in clinical research and development, Belgium is a hub of expertise in Europe. The country's excellent research infrastructure, supportive regulatory environment, focus on patient-centered treatment, and dedication to partnering with other nations and promoting global cancer research are major contributing factors to the market growth. Moreover, there is growing interest in novel trial designs, such as adaptive designs and basket trials, which may aid in the discovery of new drugs.

Market Restraints

There are also some obstacles that might limit the expansion of oncology clinical trials in Belgium, such as patient recruiting and retention problems, increased competition for trial participation from other countries, and inadequate resources for running large-scale research.

Competitive Landscape

Key Players

Pfizer Inc.
Roche Holding AG
Novartis International AG
Merck & Co., Inc.
AstraZeneca plc
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
UCB (BEL)
Janssen Pharmaceutica (BEL)
Galapagos NV (BEL)
ThromboGenics NV (BEL)
OncoDNA (BEL)

Notable Insights

January 2023, Enlivex has been granted permission by the French Agency for Food, Environmental, and Occupational Health and Safety (ANSES) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) to expand recruitment for its phase 2 clinical trial of Allocetra (NCT04612413) into France and Belgium.
In September 2022, The Belgian Cancer Research Consortium was formed when five Belgian cancer research organizations agreed to collaborate in order to leverage their efforts and improve strategic cooperation between individual researchers and organizations.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.